Mounjaro vs Wegovy — Which GLP-1 Works Better for Weight Loss?

If you’ve been prescribed a GLP-1 medication — or you’re researching your options — the question almost every patient lands on is the same: Mounjaro or Wegovy? Both are weekly injections. Both suppress appetite and drive significant weight loss. But the data now shows they are not interchangeable, and choosing the right one can make a real difference in your results and your experience.

This guide breaks down everything you need to know: how each medication works, what the clinical trials actually show, how their side effect profiles differ, what they cost, and who tends to do better on each.

What Are Mounjaro and Wegovy?

Wegovy is the brand name for semaglutide 2.4 mg, approved by the FDA specifically for chronic weight management. It’s made by Novo Nordisk and was approved for obesity in 2021. You may also have heard of Ozempic — that’s the same molecule (semaglutide) at a lower dose, approved for type 2 diabetes. Wegovy is dosed weekly by subcutaneous injection, titrated up over several months.

Mounjaro is the brand name for tirzepatide, made by Eli Lilly. Mounjaro was originally approved for type 2 diabetes, while Zepbound — the same molecule at the same doses — is the FDA-approved brand for weight management. In practice, many patients and providers use the names Mounjaro and Zepbound interchangeably. Like Wegovy, it’s a weekly injection titrated up gradually.

Both are GLP-1 receptor agonists at their core, but that’s where a critical difference begins.

The Key Mechanism Difference

Wegovy (semaglutide) works by mimicking GLP-1 — a hormone your gut releases after eating. GLP-1 slows gastric emptying, reduces appetite, and signals the brain that you’re full. It’s a single-receptor agonist, and it’s highly effective.

Mounjaro (tirzepatide) does all of that and more. It’s a dual-agonist: it activates both GLP-1 receptors and GIP receptors (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone involved in fat storage, insulin secretion, and energy balance. By hitting both pathways simultaneously, tirzepatide produces a stronger and more sustained metabolic response than semaglutide alone.

This dual mechanism is the reason the clinical trial results look so different.

What the Clinical Trials Actually Show

The SURMOUNT-5 Head-to-Head Trial

The most important study for this comparison is SURMOUNT-5, a Phase IIIb randomized controlled trial that put tirzepatide and semaglutide directly against each other in adults with obesity (without type 2 diabetes). This was the head-to-head comparison the field had been waiting for.

The results were striking:

• Tirzepatide (Mounjaro/Zepbound): average weight loss of 20.2% of body weight
• Semaglutide (Wegovy): average weight loss of 13.7% of body weight
• Tirzepatide provided 47% greater relative weight loss compared to semaglutide

To put that in real-world terms: for someone starting at 250 lbs, tirzepatide would be expected to produce roughly 50 lbs of weight loss, compared to about 34 lbs on semaglutide. That’s a meaningful gap.

The SURMOUNT-1 and STEP Trials (Individual Data)

Before the head-to-head trial, we had data from separate programs:

• SURMOUNT-1 (tirzepatide): Participants lost up to 22.5% of body weight at the highest dose (15 mg) over 72 weeks
• STEP 1 (semaglutide): Participants lost up to 14.9% of body weight over 68 weeks

These trials used different populations and designs, making direct comparison imperfect — which is exactly why SURMOUNT-5 was so valuable when it confirmed the gap in a controlled setting.

Real-World Data

A large JAMA Internal Medicine cohort study of real-world patients also found tirzepatide users lost significantly more weight than semaglutide users in routine clinical settings, not just in tightly controlled trials. This matters because trial populations don’t always reflect the messy reality of real patients with varying adherence, comorbidities, and medication access.

Side Effect Profiles: How Do They Compare?

Both medications share similar GI side effects — particularly during dose escalation — because both activate GLP-1 receptors in the gut.

Common to both:

• Nausea (most common, usually worse early in treatment)
• Vomiting
• Diarrhea or constipation
• Reduced appetite
• Fatigue

Constipation is especially common on both medications. GLP-1 agonists slow gut motility significantly, and many patients find this to be the side effect that most affects their daily life. If constipation is a concern for you, our GLP-1 Constipation Relief Guide has a full protocol for managing it.

Is one medication harder on the stomach than the other?

In SURMOUNT-5, GI side effects were slightly more common with tirzepatide than with semaglutide, which some researchers attribute to the stronger dual-agonist effect. However, the rates weren’t dramatically different, and most patients tolerate both medications well with a slow titration schedule.

Injection site reactions are possible with both. Gallbladder issues (gallstones, cholecystitis) have been reported with both, likely because rapid weight loss increases gallstone risk regardless of the medication.

Thyroid considerations: Both carry a boxed warning about medullary thyroid carcinoma based on rodent studies. Neither should be used in people with a personal or family history of MTC or MEN2.

Cost: What Will You Actually Pay?

Cost is one of the most practical factors in this decision, and it varies widely depending on your insurance.

Without insurance:

• Wegovy (semaglutide): Retail price around $1,300–$1,500/month; NovoCare savings program brings it to approximately $199/month for eligible patients through the end of 2026
• Mounjaro/Zepbound (tirzepatide): Retail around $1,300+/month; LillyDirect self-pay options start around $499/month

With insurance: Coverage varies enormously. Many commercial insurance plans cover at least one of these medications, but coverage for obesity specifically (as opposed to type 2 diabetes) is still inconsistent. Medicare Part D began covering anti-obesity medications in 2026, which has improved access significantly for older patients.

The practical reality: whichever medication your insurance covers better is often the right starting point. Both are effective, and a medication you can afford and stay on consistently will always beat a theoretically superior medication you can’t access.

For patients in the US without good insurance coverage, patient assistance programs, telehealth prescribers, and compounding options (where legally available) are all paths worth exploring with your provider.

Who Is Each Medication Best For?

Mounjaro/Zepbound (tirzepatide) may be a better fit if:

• You want the maximum available weight loss and are willing to start at the higher-efficacy option
• You have type 2 diabetes (tirzepatide was originally approved for T2D and has strong glycemic data)
• Your provider and insurance support it
• You’ve tried semaglutide and plateaued or didn’t see enough results

Wegovy (semaglutide) may be a better fit if:

• It’s better covered by your insurance or more affordable in your situation
• Your provider has more experience prescribing it
• You’re 12 or older (Wegovy is approved for adolescents; Zepbound is currently approved for adults only)
• You want to start with an established, widely studied option with a longer track record

Important: This is not a decision to make based on internet research alone. Your prescriber knows your full medical history, any comorbidities that affect the choice, and what’s covered by your insurance. Use this comparison to have a more informed conversation with them — not to self-prescribe.

What About Medication Adherence?

Here’s the thing that the clinical data sometimes obscures: the best GLP-1 medication is the one you stay on. Research consistently shows that a large percentage of patients stop GLP-1 medications within the first year, often because of unmanaged side effects.

If you’re going to get results — whether you’re on Mounjaro or Wegovy — you need a plan for managing the side effects that most commonly cause people to quit. That means understanding your gut health, optimizing your fiber and protein intake, and having strategies ready for the nausea and constipation that tend to peak in the first few months.

Our GLP-1 Comfort Guide is built specifically for this: a practical, evidence-based toolkit for staying comfortable and consistent on your medication, whatever brand you’re taking.

And if you want a comprehensive understanding of the science behind GLP-1 medications, obesity biology, and what the research actually says about long-term weight management, the Obesity & GLP-1 Guide covers all of it in depth.

The Bottom Line

When the data is taken as a whole, tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Wegovy) — roughly 20% vs 14% in the head-to-head SURMOUNT-5 trial, a 47% relative difference. That’s a clinically meaningful gap.

But medication choice is never just about efficacy numbers. Cost, insurance coverage, your medical history, age, and what side effects you’re able to tolerate all factor in. Both medications are genuinely effective, both are weekly injections, and both require a commitment to the process.

The goal isn’t to pick the “winning” medication on paper — it’s to find the right fit for your body, your situation, and your long-term health. Work with your provider, come prepared with the right questions, and use every tool available to stay consistent.

If constipation or other side effects are making your GLP-1 journey harder, explore our full GLP-1 Resource Bundle — designed to help you stay comfortable, informed, and on track from week one.

---

Always consult your healthcare provider before starting, stopping, or changing any medication. The information in this article is educational and does not constitute medical advice.